Literature DB >> 22550337

Expression and prognostic value of ING3 in human primary hepatocellular carcinoma.

Hai-Yan Yang1, Hao-Ling Liu, Lan-Tian Tian, Rui-Peng Song, Xuan Song, Da-Long Yin, Ying-Jian Liang, Lian-Dong Qu, Hong-Chi Jiang, Jia-Ren Liu, Lian-Xin Liu.   

Abstract

The tumor-suppressor ING3 has been shown to be involved in tumor transcriptional regulation, apoptosis and the cell cycle. Some studies have demonstrated that ING3 is dysregulated in several types of cancers. However, the expression and function of ING3 in human hepatocellular carcinoma (HCC) remains unclear. The aim of this study is to investigate ING3 expression in hepatic tumors and its clinical relevance in hepatic cancer. The expression of ING3 protein was examined in 120 dissected HCC tissues and 47 liver tissues adjacent to the tumor by immunohistochemical assays and confirmed by Western blot analysis in 20 paired frozen tumor and non-tumor liver tissues. The relationship between ING3 staining and clinico-pathological characteristics of HCC was further analyzed. The mRNA expression of ING3 in the dissected tissues was also analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) and realtime PCR. Both mRNA and protein concentrations of ING3 were found to be downregulated in the majority of HCC tumors in comparison with matched non-tumor hepatic tissues. Analysis of the relationship between ING3 staining and clinico-pathological characteristics of HCC showed that the low expression of ING3 protein is correlated with more aggressive behavior of the tumor. Kaplan-Meier curves demonstrated that patients with a low expression of ING3 have a significantly increased risk of shortened survival time. In addition, multivariate analysis suggested that the level of ING3 expression may be an independent prognostic factor. Our findings indicate that ING3 may be an important marker for human hepatocellular carcinoma progression and prognosis, as well as a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550337     DOI: 10.1258/ebm.2011.011346

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  7 in total

1.  Molecular cloning and expression analysis of inhibitor of growth protein 3 (ING3) in the Manila clam, Ruditapes philippinarum.

Authors:  Guang-Wei Hu; Xi-Wu Yan; Yan-Jie Qin; Hong-Tao Nie
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

2.  ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.

Authors:  Amal Almami; Samar A Hegazy; Arash Nabbi; Mohammed Alshalalfa; Asma Salman; Hatem Abou-Ouf; Karl Riabowol; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-01-23

3.  Downregulation of nuclear ING3 expression and translocalization to cytoplasm promotes tumorigenesis and progression in head and neck squamous cell carcinoma (HNSCC).

Authors:  Xiaohan Li; Qun Zhang; Mingming Zhang; Yusong Luo; Yaping Fu
Journal:  Histol Histopathol       Date:  2019-12-30       Impact factor: 2.303

4.  Immunohistochemical profile of ING3 protein in normal and cancerous tissues.

Authors:  Wen-Feng Gou; Xue-Feng Yang; Dao-Fu Shen; Shuang Zhao; Hong-Zhi Sun; Jun-Sheng Luo; Hua-Chuan Zheng
Journal:  Oncol Lett       Date:  2017-01-23       Impact factor: 2.967

Review 5.  ING Tumour Suppressors and ING Splice Variants as Coregulators of the Androgen Receptor Signalling in Prostate Cancer.

Authors:  Anna Melekhova; Aria Baniahmad
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

6.  ING3 promotes prostate cancer growth by activating the androgen receptor.

Authors:  Arash Nabbi; Urszula L McClurg; Subhash Thalappilly; Amal Almami; Mahsa Mobahat; Tarek A Bismar; Olivier Binda; Karl T Riabowol
Journal:  BMC Med       Date:  2017-05-16       Impact factor: 8.775

7.  Loss of Ing3 Expression Results in Growth Retardation and Embryonic Death.

Authors:  Dieter Fink; Tienyin Yau; Arash Nabbi; Bettina Wagner; Christine Wagner; Shiting Misaki Hu; Viktor Lang; Stephan Handschuh; Karl Riabowol; Thomas Rülicke
Journal:  Cancers (Basel)       Date:  2019-12-29       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.